MX2022012618A - Aptameros para uso en el tratamiento de infecciones por coronavirus. - Google Patents
Aptameros para uso en el tratamiento de infecciones por coronavirus.Info
- Publication number
- MX2022012618A MX2022012618A MX2022012618A MX2022012618A MX2022012618A MX 2022012618 A MX2022012618 A MX 2022012618A MX 2022012618 A MX2022012618 A MX 2022012618A MX 2022012618 A MX2022012618 A MX 2022012618A MX 2022012618 A MX2022012618 A MX 2022012618A
- Authority
- MX
- Mexico
- Prior art keywords
- viruses
- coronaviridae
- aptamers
- treatment
- molecules
- Prior art date
Links
- 108091023037 Aptamer Proteins 0.000 title abstract 4
- 208000001528 Coronaviridae Infections Diseases 0.000 title 1
- 241000711573 Coronaviridae Species 0.000 abstract 4
- 241000700605 Viruses Species 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 3
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000001082 somatic cell Anatomy 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20168929 | 2020-04-09 | ||
| EP20176023 | 2020-05-22 | ||
| EP20180781 | 2020-06-18 | ||
| EP20204036 | 2020-10-27 | ||
| PCT/EP2021/059328 WO2021205012A1 (en) | 2020-04-09 | 2021-04-09 | Aptamers for use in the treatment of coronaviridae infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012618A true MX2022012618A (es) | 2022-11-07 |
Family
ID=84191962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012618A MX2022012618A (es) | 2020-04-09 | 2021-04-09 | Aptameros para uso en el tratamiento de infecciones por coronavirus. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12606828B2 (https=) |
| EP (1) | EP4133083A1 (https=) |
| JP (1) | JP2023521361A (https=) |
| KR (1) | KR20220166337A (https=) |
| CN (1) | CN115768895A (https=) |
| AU (1) | AU2021252151A1 (https=) |
| BR (1) | BR112022020439A2 (https=) |
| CA (1) | CA3175067A1 (https=) |
| IL (1) | IL297155A (https=) |
| MX (1) | MX2022012618A (https=) |
| ZA (1) | ZA202212179B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230170931A (ko) * | 2021-04-09 | 2023-12-19 | 베를린 큐어스 게엠베하 | 코로나바이러스 감염 치료에 사용하기 위한 압타머 |
| KR102937192B1 (ko) * | 2023-01-25 | 2026-03-17 | 주식회사 리젠시스랩 | 사스 코로나 바이러스 2 특이적 압타머 및 이의 용도 |
| WO2025146959A1 (ko) * | 2024-01-02 | 2025-07-10 | 충북대학교 산학협력단 | ＳＡＲＳＣｏＶ２의 외피 단백질에 특이적으로 결합하는 ＤＮＡ 앱타머 및 이의 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MEP0208A (xx) * | 2005-08-26 | 2010-02-10 | Archemix Corp | Aptameri koji vezuje trombin sa visokim afininitetom |
| EP2497828A1 (en) * | 2011-03-07 | 2012-09-12 | Charité - Universitätsmedizin Berlin | Use of aptamers in therapy and/or diagnosis of autoimmune diseases |
| CN117653654A (zh) * | 2016-11-23 | 2024-03-08 | 柏林制药股份有限公司 | 用于抑制和/或压制tlr9激活的适体 |
-
2021
- 2021-04-09 KR KR1020227039288A patent/KR20220166337A/ko active Pending
- 2021-04-09 CN CN202180041090.7A patent/CN115768895A/zh active Pending
- 2021-04-09 BR BR112022020439A patent/BR112022020439A2/pt unknown
- 2021-04-09 JP JP2022561426A patent/JP2023521361A/ja active Pending
- 2021-04-09 AU AU2021252151A patent/AU2021252151A1/en active Pending
- 2021-04-09 US US17/995,705 patent/US12606828B2/en active Active
- 2021-04-09 EP EP21716761.8A patent/EP4133083A1/en active Pending
- 2021-04-09 MX MX2022012618A patent/MX2022012618A/es unknown
- 2021-04-09 CA CA3175067A patent/CA3175067A1/en active Pending
- 2021-10-14 IL IL297155A patent/IL297155A/en unknown
-
2022
- 2022-11-08 ZA ZA2022/12179A patent/ZA202212179B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230140490A1 (en) | 2023-05-04 |
| ZA202212179B (en) | 2025-03-26 |
| KR20220166337A (ko) | 2022-12-16 |
| CA3175067A1 (en) | 2021-10-14 |
| US12606828B2 (en) | 2026-04-21 |
| EP4133083A1 (en) | 2023-02-15 |
| IL297155A (en) | 2022-12-01 |
| JP2023521361A (ja) | 2023-05-24 |
| AU2021252151A1 (en) | 2022-12-08 |
| CN115768895A (zh) | 2023-03-07 |
| BR112022020439A2 (pt) | 2022-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001949A1 (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso (divisional de solicitud de patente no. 3422-2020) | |
| MX2022012618A (es) | Aptameros para uso en el tratamiento de infecciones por coronavirus. | |
| MX2022013301A (es) | Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa. | |
| BR112022021962A2 (pt) | Imidazopiridazinas como moduladores de il-17 | |
| CL2022002951A1 (es) | Composiciones de arni del factor b del complemento (cfb) y métodos para su uso. | |
| ECSP19025350A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| MX360728B (es) | Metodos y composiciones para virus vivos atenuados. | |
| CU23880B1 (es) | Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi) | |
| AR077333A1 (es) | Anticuerpos humanos de alta afinidad para la angiopoyetina -2 humana | |
| NI200900205A (es) | Nuevos péptidos inhibidores de la replicación del virus de la hepatitis c. | |
| BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
| BR112015023797A2 (pt) | proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17 | |
| MX2018010828A (es) | Medio para formar colonias y uso de este. | |
| CL2023001062A1 (es) | Compuestos fosfolípidos y usos de estos | |
| CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| CO2023001681A2 (es) | Bancos de células t específicas para antígeno universal y métodos para producir y usar los mismos terapéuticamente | |
| CL2022003390A1 (es) | Métodos para tratar o prevenir las infecciones de sars-cov-2 y covid-19 con anticuerpos antiglicoproteína de espiga de sars-cov-2. | |
| MX2025004075A (es) | Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos | |
| BR112022021957A2 (pt) | Imidazopirimidinas como moduladores de il -17 | |
| AR083546A1 (es) | Tratamiento de inflamacion gastrointestinal, soriasis y asma | |
| MX2022015365A (es) | Composiciones y métodos para el tratamiento del covid largo. | |
| AR105541A1 (es) | ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR VRSh | |
| CL2025003288A1 (es) | Anticuerpos que se unen a ox40l y métodos de uso. | |
| MX2022009776A (es) | Tratamiento de la colangitis biliar primaria con elafibranor. | |
| MX2022002400A (es) | Tratamiento de los sintomas inducidos por el ciclo menstrual. |